Primary Care

Discussion in 'Merck' started by anonymous, Jun 11, 2016 at 10:11 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    HAHAHAHA! Come on dude, quit being so mean! These CTL's actually think they are of value! Don't let them know the facts speak otherwise!
     

  2. anonymous

    anonymous Guest

    True that
     
  3. anonymous

    anonymous Guest

    All of you useless fraudulent shitheads will soon be history and what a glorious ending. My returns will skyrocket! Enjoy the welfare line scum!
     
  4. anonymous

    anonymous Guest

    Sam Spade here, been doing some investigating

    Merck is on solid ground. Several products and many more in the pipeline. If our reps will just get out in the streets and properly execute around the marketing message of Belsomara and articulate the benefits of strong efficacy with Januvia this company will continue to roll in the cash and maintain jobs for everyone.

    So take heed my friends, don't let rumors and slanderous people create anxiety for you. Just go make your 8.5 calls and capitalize on those RFM opportunities. Listen to your coaches and success awaits you all.

    Your career will one day come to a conclusion and you will cash in with millions in your pension. Isn't Merck just dreamy.
     
  5. anonymous

    anonymous Guest

    Hey Sam,

    Completely agree with your plan. Only problem, 30 years too late. In 1986 everything applied. Back then we had products that we could differentiate and brought value to the 8.5+ doctors we could actually talk to at their desks for 10-15 minutes per call anytime of day. Conference calls didn't exist then and we barely had time for meetings because we were too busy with customers. For that matter, didn't have time for lunch. Now, only discussion over 30 seconds is a lunch rfm and conference calls & compliance tests give us something to put on our calendars. The good news for those few of us who started in the '80s & '90s, we do have those seven figure pensions you referenced to keep us going.
     
  6. anonymous

    anonymous Guest

    You should have seen the early 80's; delightful; nothing like today.
     
  7. anonymous

    anonymous Guest

    CTL

    This is an outdated business model that only serves to keep senior managers employed.

    Span of control 1:20 would be good but that would require a huge reduction costing directors their precious positions.

    They serve little value in an evolving pharma environment. The payor is increasingly dictating Rx leaving the provider with little influence thus the rep even less. Marketing is clueless. Always letting reps know it's about efficacy. Well that's news nobody knew. If it does not work you mean they won't prescriber. Shocker. After the efficacy puzzle piece is In place it's about access, cost and relationship. However marketing can't say that because they would put themselves out of a job.

    Suggestion would be to clip half the PC management team and half the marketing team. Company saves millions and u still have people to drive some revenue.
     
  8. anonymous

    anonymous Guest

     
  9. anonymous

    anonymous Guest

    Face the facts kiddos, all of you will be gone very soon. I am inside and have seen all the plans there is no doubt!
     
  10. anonymous

    anonymous Guest

    You just put a very big spotlight on the aging elephant in the room. Amazing that Frazier has not acted on this yet seeing as how his business model is all about expense reduction.
     
  11. anonymous

    anonymous Guest


    When will the hammer drop?
     
  12. anonymous

    anonymous Guest

    10/6/2016
     
  13. anonymous

    anonymous Guest

    The hammer dropped about 40,000 former employees ago. You must have missed it.